Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Clinical trial NCT06708858 · RECRUITING
Trial details
- NCT number
- NCT06708858
- Sponsor
- Dai, Guanghai
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-15
- Primary completion
- 2025-12-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.